ImmuneSpec SRL
5.7 FTEThe score of ImmuneSpec shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +38 % Total assets +10 % Headcount (avg FTE) +235 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ImmuneSpec's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Jun 2026
- Year ended 31 Dec 2024filed on 28 May 2025
- Year ended 31 Dec 2023filed on 11 Jun 2024
ImmuneSpec's financial analysis
- Solvency74.6%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ImmuneSpec
ImmuneSpec's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0797.707.610
- VAT number
- BE0797707610
- Peppol
- Registered · 0208:0797707610 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 27 Jan 2023
- Registered office
- 2845 Niel
- Size
- Micro · 5.7 FTE
- Latest accounts
- 2025 · filed on 08 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
ImmuneSpec (SRL) has been based in Niel since 2023, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 201,723 € and equity of €2.64m; its revenue is not published. With 5.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 74.6%, above the median of its sector (60.4%).
Companies similar to ImmuneSpec
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- K5 Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €3.56m
- Envitec Measurements AND Analytics SA Research and experimental development on natural sciences and engineering Gembloux · balance sheet €3.64m
- HepaVue Dx Research and experimental development on natural sciences and engineering Waterloo · balance sheet €3.71m
- Dr. J. Bellon Research and experimental development on natural sciences and engineering Buggenhout · balance sheet €3.14m
- Elmace Research and experimental development on natural sciences and engineering Aalter · balance sheet €3.11m
- Pacira Belgium Research and experimental development on natural sciences and engineering Eupen · balance sheet €3.00m
- Montis Biosciences Research and experimental development on natural sciences and engineering Leuven · balance sheet €2.97m
Frequently asked questions about ImmuneSpec
What is the revenue of ImmuneSpec?
ImmuneSpec files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ImmuneSpec?
In Belgium, the VAT number is the company number prefixed with BE: BE0797707610 for ImmuneSpec, if the company is VAT-registered. Its company number (CBE) is 0797.707.610.
Where is the registered office of ImmuneSpec?
According to the CBE register, the registered office of ImmuneSpec is in 2845 Niel.
What is the equity of ImmuneSpec?
At the close of the 2025 financial year, the equity of ImmuneSpec amounts to 2,638,403 €, a solvency of 74.6% of total assets.
How many people work at ImmuneSpec?
5.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ImmuneSpec?
The register lists 6 active mandates at ImmuneSpec. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of ImmuneSpec
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →